It is like rats jumping off a sinking ship. Pfizer is going to stop research and development of heart drugs. It is not profitable for the drug giant to continue to fool the public with its uselss poison, it is dumping this side of its business. But is it going to have anything better to offer of another potential blockbuster for any chronic diseases that it is interested in developing? Personally, I doubt it.
“New York, NY - Pfizer is getting out of the cholesterol-lowering game to focus on what it perceives to be more lucrative diseases, according to an internal memo obtained by Forbes [1]. And for the most part, the chosen “disease areas” don’t include the heart.
In the memo, Martin Mackay, president of Pfizer Global Research & Development (R&D), informed his staff that the company plans to “exit” the fields of atherosclerosis/hyperlipidemia, heart failure, obesity, and peripheral arterial disease.
Instead, the company, whose cholesterol-lowering drug atorvastatin (Lipitor) is the world’s top-selling drug, says it is turning its attention and R&D dollars to cancer, diabetes, Alzheimer’s, pain remedies, and mental health as its “higher-priority areas.” “
Read the full article: http://www.theheart.org/article/908435.do